An Exciting Time for Research into CTEPH Discussed in Review Article

Patients with pulmonary hypertension may be surprised to know that the disease can sometimes be accompanied by the complication known as thromboembolic pulmonary hypertension (CTEPH). Pulmonary embolisms are the root cause of CTEPH because a pulmonary embolism (a blood clot in the lungs) that fails to be degraded via thromboembolysis can become lodged in blood vessels leading to the lungs and occlude blood flow. Individuals without any history of pulmonary embolisms are susceptible to CTEPH, making it important to understand the pathophysiology, risks factors, and signs of CTEPH.

 

As suggested by a recent review entitled, “Chronic Thromboembolic Pulmonary Hypertension: the End Result of Pulmonary Embolism,” which was published in Current Cardiology Reports, it is an exciting time for researchers in the field of CTEPH and patients who suffer from the disease. A lot of progress has been made in understanding CTEPH, leading to better diagnosis techniques and therapeutic options.

“Although it is generally believed that CTEPH originates with acute venous thromboembolism, interestingly, up to 40% of CTEPH patients will have no antecedent history suggestive of acute pulmonary embolism,” wrote Dr. Alison S. Witkin and Dr. Richard N. Channick, of the Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital in Boston.

Often times, CTEPH symptoms are confused with those of other cardiac and pulmonary diseases, which can lead to delays between first notice of symptoms and CTEPH diagnosis. Shortness of breath, progressive exercise intolerance, and chest pain are all indicators of some form of pulmonary hypertension. However, a large difference between pulmonary arterial hypertension and CTEPH is the type of blood vessels that are affected. Pulmonary arterial hypertension affects blood vessels smaller than 300 micrometers in size, while CTEPH affects larger blood vessels that are closer to the heart.

Since patients and their clinicians may not suspect CTEPH is the root cause of symptoms due to the disconnect between patient history and the ease of coming to an improper diagnose, it is important to have a standard technique to diagnose CTEPH. Commonly, ventilation perfusion scans are used to suggest CTEPH, but the gold standard to properly diagnose CTEPH is via right heart catheterization and pulmonary artery angiogram. These may be performed when patients have the indicative symptoms for CTEPH and have some of the common risk factors: idiopathic pulmonary embolism, large perfusion defects, and a right ventricular systolic pressure greater than 50 mmHg.

Once properly diagnosed, CTEPH, unlike other forms of pulmonary hypertension, can be cured by the surgical procedure known as pulmonary thromboendarterectomy (PTE). Recently, a medication developed by Bayer, Adempas (riociguat), was approved by the Food and Drug Administration for patients with CTEPH. Adempas is also indicated for pulmonary arterial hypertension, as the drug acts to increase vessel diameter to allow blood to flow more easily, reducing the pressure the heart must work against to pump blood to the lungs.

Because there are viable treatment options for those with CTEPH, the most significant unmet medical need for addressing the disease is improving early detection, since patient outcomes are hinged on how early an accurate CTEPH diagnosis is made. With researchers making substantial progress in improving early detection of CTEPH, the medical community is becoming increasingly capable of treating and curing people with the disease.

Comment

  • SoloTex SoloTex Thursday, 02 July 2015

    payday loans gun barrel city tx

    payday express

    payday express

    payday loan bountiful utah

  • YlosTex YlosTex Thursday, 02 July 2015

    viagra 100 mg effets

    viagra coupons

    cheap viagra

    cialis viagra buy online

  • Johnpracy Johnpracy Thursday, 02 July 2015

    payday loan online

  • YlosTex YlosTex Thursday, 02 July 2015

    pfizer offers viagra online

    http://viagragche.com/ - viagra coupons

    buy cheap viagra

    viagra scaduto e pericoloso

  • SoloTex SoloTex Thursday, 02 July 2015

    minnesota payday loan lenders

    payday loans online

    payday loans online

    top cash advance in Washington DC

  • SoloTex SoloTex Thursday, 02 July 2015

    direct payday loan lenders same day

    pay day loans

    pay day loans

    first american payday loans

  • SoloTex SoloTex Thursday, 02 July 2015

    payday cash advance wisconsin

    http://soloadvance.com/ - loans for bad credit

    cash advance

    bad credit loans in colorado springs

  • OlegTex OlegTex Thursday, 02 July 2015

    cash advance 103rd st jacksonville fl

    payday loans

    loans for bad credit

    cash advance network customer service

  • SoloTex SoloTex Thursday, 02 July 2015

    cash advance Cols 43221

    payday loans

    cash advance

    small loans low apr

  • OlegTex OlegTex Thursday, 02 July 2015

    quick loans no hassle

    cash advance

    pay day loans

    what are the chances of me getting a loan with bad credit

Leave your comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

About Us

The Saudi Association for Pulmonary Hypertension (SAPH) is a medical and research national group of many medical specialists, who shared a common interest in the field of pulmonary vascular disease. The main goal for SAPH is to increase the awareness and the knowledge of pulmonary vascular diseases in the society and between the medical professionals.

The Saudi Association for Pulmonary Hypertension (SAPH) is a Subsidiary of The

Saudi Association for PH

STS office (Exit 11 & the Airport Road)

Riyadh, Saudi Arabia

P. O. Box 106911
Riyadh 11676
Saudi Arabia

Tel:+966-11-2488966
Fax: +966-11-2487431
Mobile:+966506426704

We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…